NCT01682083 2026-04-21
COMBI-AD
Novartis
Phase 3 Completed
Novartis
Bristol-Myers Squibb
Regeneron Pharmaceuticals
Merck Sharp & Dohme LLC
Pfizer
Hoffmann-La Roche
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Kyowa Kirin Co., Ltd.
Delcath Systems Inc.